BiondVax stock: buy or sell?
May 14th, 2020
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel.
Should I buy BiondVax stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with BiondVax Pharmaceuticals stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is BiondVax stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for BVXV stock for the last 30 days.
BiondVax stock analysis
After marking all time highs on May 7th, BiondVax collapsed -5.06% to $15.40.
BiondVax Pharmaceuticals collapsed -5.06% today to $15.40 after marking all time highs on May 7th. Since last March when BVXV stock price broke up the SMA200d line, it gained $9.20 (148.39%). BVXV is soaring again after a 15.56% correction from its last top on May/7 at $18.00. Since SMA50d and SMA100d crossed up today, BVXV price slid a -5.06%. On May 7th, BVXV hit new all time highs, pushing higher previous ATH of $17.95 recorded on Apr 30th. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
After climbing for 4 weeks, this week BiondVax Pharmaceuticals declined a lame -1.09%, closing at $15.40. Last week BVXV rocketed an outstanding 12.01% in just one week.
In a weekly time frame, BiondVax Pharmaceuticals stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, BVXV might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last price record BiondVax Pharmaceuticals marked last week. Late March BVXV price bounced up over the SMA of 40 weeks that acted as support stopping new slides. Early January, SMA20w and SMA40w crossed up triggering a rise of 60.75%.
BiondVax stock price history
BiondVax stock went public on May 12th, 2015 with a price of $4.891. Since then, BVXV stock grew a 214.90%, with an average of 43.00% per year. If you had invested $1,000 in BiondVax stock in 2015, it would worth $2,149.00 today.
1: Adjusted price after possible price splits or reverse-splits.
BiondVax stock historical price chart
BVXV stock reached all-time highs on May 7th with a price of $18.00.
BiondVax stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not found any price prediction for BiondVax Pharmaceuticals stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, BiondVax reported its latest financial data, posting a super good gain for the Earnings per Share (EPS). Experts were expecting $-0.01 per share, but BiondVax posted $-0.11.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , BiondVax Pharmaceuticals annual sales to M dollars from marked in . , its income margin (compared to revenues) to , that is million.
Quarterly financial resultsReported quarter income marked $-2.25 million with a profit margin of . Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, BiondVax Pharmaceuticals sales marked a neutral movement and remained constant a nan%. Looking back to recent quarterly results, BiondVax Pharmaceuticals posted 6 negative quarters in a row.
BiondVax ownershipWhen you are planning to invest in a company, it's worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For BiondVax Pharmaceuticals, 22.93% of all outstanding shares are owned by its staff.
In case of BiondVax stock, 0.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BVXV stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$154.9 M|
|Total shares||10.1 M|
|Float shares||5.3 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||22.9%|
|Shares in short selling||0.0%|
|Thursday, May 14th, 2020|
|Day range||$15.00 - $16.62|
|Average true range||$2.02|
|50d mov avg||$9.57|
|100d mov avg||$9.55|
|200d mov avg||$7.73|
BiondVax performanceTo better understand BiondVax performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare BiondVax performance to :